I noticed the same point. Practically this increases the statistical significance. Decreasing the chance that PAA was just lucky with the patients it recruited and increasing the probability that Monepantel is an effective treatment. Highly overlooked by the market at this stage.
Ann: Positive Interim Study Results from OLE Study in ALS, page-32
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $31.22K | 164.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 362647 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 66191 | 2 |
View Market Depth
| Last trade - 14.37pm 05/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |